- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide (AC2993), Insulin glargine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 21
- States / cities
- San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,095
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 85
- States / cities
- Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
- Conditions
- Surgery-Complications, Respiratory Complication, Lung Injury, Acute
- Interventions
- Dexmedetomidine Hydrochloride, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Lubiprostone, Placebo
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 71 more
- Conditions
- HIV-1 and Hepatitis C Co-Infection
- Interventions
- pioglitazone, peginterferon, ribavirin
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Kidney Transplantation
- Interventions
- Mycophenolate mofetil, Cyclosporine, Tacrolimus
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 13 Years to 75 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more
- Conditions
- Asthma
- Interventions
- E004 (Epinephrine Inhalation Aerosol) HFA-MDI, Placebo-HFA
- Drug
- Lead sponsor
- Amphastar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 8
- States / cities
- Costa Mesa, California • Orange, California • Stockton, California + 5 more
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- abaloparatide, abaloparatide solid microstructured transdermal system
- Combination Product
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years · Female only
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
- Interventions
- 5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Otitis
- Interventions
- Saline, Fentanyl, Dexmedetomidine
- Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 6 Months to 6 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- HIV
- Interventions
- DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
- Interventions
- Levonorgestrel IUS, Tranexamic Acid
- Drug
- Lead sponsor
- Shannon K. Laughlin-Tommaso
- Other
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Multiple Sclerosis
- Interventions
- BG9418 (interferon beta 1-a)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Dallas, Texas
- Conditions
- Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
- Interventions
- Livmarli
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Osteoporosis
- Interventions
- Parathyroid Hormone-related Protein
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 24 Years to 35 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Atrial Fibrillation
- Interventions
- Tecadenoson, Esmolol
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
- Interventions
- 18F-DCFPyL, 18F-FDG, PSMA-11
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Asthma
- Interventions
- ARS-1 1 mg, Albuterol MDI, Placebo, ARS-1 2mg
- Drug
- Lead sponsor
- ARS Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Chevy Chase, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Prostate Cancer
- Interventions
- Vitamin E, Selenium, Vitamin E placebo, selenium placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 50 Years to 120 Years · Male only
- Enrollment
- 35,533 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2012
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Joliet, Illinois • Maywood, Illinois + 8 more
- Conditions
- Influenza, Influenza Immunisation
- Interventions
- Influenza Multimeric-001 Vaccine, Placebo, Quadrivalent Recombinant Seasonal Influenza Vaccine
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas
- Conditions
- Bradycardia, Arrhythmias
- Interventions
- Atropine
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 15
- States / cities
- Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more